EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis

Luqing Zhao, Zhiting Zhao, Xiaoqi Yan, Xiao Hu, Jifeng Feng iD, Shaorong Yu

Technology in Cancer Research & Treatment · 2024-01 · 23

DOI: 10.1177/15330338241227055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 22.01.2024. Verfasst von Luqing Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer …. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Life Oasis Public Service Center, “Six Talent Peaks” of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

As monotherapy such as topotecan has reached a plateau of effectiveness, new second-line treatments based on experience have been used in clinical application. This study compared the efficacy and safety of different second-line treatments for advanced small-cell lung cancer (SCLC).

Methods

A total of 380 patients with advanced SCLC were screened selectively in the retrospective study. Adverse events and patient responses were assessed using Common Terminology Criteria for Adverse Events v5.0 and Response Evaluation Criteria for Solid Tumors v1.1. The progression-free survival (PFS) was estimated using the Kaplan-Meier method or Cox survival regression model and compared using the log-rank test.

Results

In the platinum-resistant group, disease control rate (DCR) and median PFS (mPFS) were prolonged in the combination group versus single-agent group (DCR: 49.24% vs 24.39%, P = .004; mPFS: 3.73 vs 1.90 months, P < .001). Grade 3/4 toxicity was similar between the 2 groups ( P = .683). The mPFS did not differ among single-agent groups ( P = .380). No significant difference was observed in mPFS of different combination therapy groups ( P = .170). In terms of platinum-based chemotherapy, the DCR and mPFS were prolonged in irinotecan-platinum group versus taxol-platinum group (DCR: 56.14% vs 9.09%, P = .004; mPFS: 3.87 vs 1.93 months, P = .012). Grade 3/4 toxicity was similar between the 2 groups ( P = .614). The mPFS was prolonged in the chemotherapy plus immunotherapy group versus single-agent chemotherapy group ( P = .003). In the platinum-sensitive group, the mPFS did not differ between the combination group and single-agent group ( P = .200). The mPFS did not differ among different single-agent groups ( P = .260) or combination groups ( P = .150). There was no difference in mPFS among different platinum-based chemotherapy groups ( P = .830).

Conclusions

For patients with platinum-resistant SCLC, combination therapy has shown better efficacy and acceptable toxicity profile than monotherapy. Among combination therapies, irinotecan–platinum has shown better efficacy than taxol–platinum. For patients with platinum-sensitive SCLC, the efficacy of different single-agent or combination therapies was similar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaHumansRetrospective StudiesIrinotecanPaclitaxelPlatinum

Stichwörter der Autor:innen

advanced SCLCchemotherapycombinationimmunotherapysecond-line treatmentsingle-agent

Substanzen

IrinotecanPaclitaxelPlatinum

Autor:innen und Institutionen

  • Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
  • Department of Oncology, The Air Force Hospital from Eastern Theater of PLA, Nanjing, China.
  • Department of Oncology, The Affiliated Suqian First People's Hospital of Nanjing Medical University & Suqian First Hospital, Suqian, China.

ORCID-Profile: Jifeng Feng

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Life Oasis Public Service Center
  • “Six Talent Peaks” of Jiangsu Province
  • Suqian Sci & Tech Program
  • Social Development Project of Jiangsu Province

Zitieren

APA

Zhao, L., Zhao, Z., Yan, X., Hu, X., Feng, J., & Yu, S. (2024). Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis. Technology in Cancer Research & Treatment, 23. https://doi.org/10.1177/15330338241227055

Vancouver

Zhao L, Zhao Z, Yan X, Hu X, Feng J, Yu S. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis. Technology in Cancer Research & Treatment. 2024;23. doi:10.1177/15330338241227055

BibTeX
@article{Zhao2024,
  author = {Zhao, Luqing and Zhao, Zhiting and Yan, Xiaoqi and Hu, Xiao and Feng, Jifeng and Yu, Shaorong},
  title = {Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  volume = {23},
  doi = {10.1177/15330338241227055}
}
Kostenlos starten →